Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are administered using convenient room temperature-stable tablets that can be stored and shipped without refrigeration.
Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and dsRNA agonists.
Our mission is the promotion of global health through the development of effective vaccines that can be administered by tablet rather than by injection, providing for the simple and efficient distribution and administration of safe vaccines in any setting.
We are looking for a SEC Reporting & Technical Accountant to join our South San Francisco team!
Summary:
The SEC Reporting and Technical Accountant has ownership and accountability for all processes related to technical accounting, SEC reporting and Equity Administration.
Responsibilities:
- Prepares external financial reporting, including 1OQ's, 1OK's and 8K's, and other financial reporting as required and review of XBRL tagging.
- Maintains quarterly reporting timetable and monitors progress against reporting cycle milestones.
- Assists in the preparation of the earnings release and reviews the financial information included in the earnings release and script.
- Assists in the preparation of definitive proxy statements.
- Prepares the quarterly/annual SEC reporting binder which includes the tie out of the relevant SEC forms being filed as well as compiling approvals received for filing.
- Participates in the monthly and quarterly close process, including preparing equity-related journal entries, stock-based compensation (SBC) calculation, and weighted shares calculation for reporting earnings per share.
- Ownership of new technical accounting projects, including M&A, and implementation of new accounting pronouncements and requirements.
- Analyzes the accounting impact and assists to implement the accounting new pronouncements.
- Coordinates and prepare the SBC reports for the tax department in their tax provision calculations and prepares the SBC forecast for FP&A budget planning.
- Supports and manages external auditors during quarterly reviews and annual audits, including preparation of disclosure checklist and financial schedules.
- A proactive approach to problem identification and remediation.
- Excellent written and oral communication skills, including the ability to interact and build relationships cross-functionally and at all levels of the organization.
- Assists in ensuring compliance with SEC and GAAP reporting requirements, including evaluation of the impact of recent and proposed pronouncements on SEC reporting.
- Research technical accounting topics and prepare memos documenting conclusions of accounting treatment.
- Stays informed of the latest rules, regulations, and reporting requirements of the SEC and FASB.
- Ensures ongoing compliance for financial reporting and leads strategic initiatives from a reporting perspective.
- Selects and implements SEC reporting and filing systems to automate the reporting process.
- Participates in special projects, and process improvement, and assists with documentation and SOX compliance.
- Supervises stock administration processes and reviews and reconciles all activity related to stock options and awards.
Requirements:
- Bachelor’s Degree in Accounting or Finance.
- CPA required.
- Minimum 12 years of progressive experience with technical accounting, auditing, and SEC reporting.
- Mix of professional experience, including a background in public accounting.
- Strong technical accounting background with a thorough knowledge of US GAAP, SOX 404(b), and SEC reporting standards, as well as experience with technical research.
- Strong analytical skills with high attention to detail and accuracy.
- Ability to prioritize tasks and meet tight deadlines.
- Intermediate/advanced skills with Microsoft Office suite, particularly Excel.
- Hands-on experience with RDG is a plus.
- Self-motivated, strong work ethic, and ability to work independently.
- Excellent interpersonal skills and ability to work well with others.
- Willing and excited to learn new skills and interested in taking on new assignments.
- Ability to promote a positive culture within a team setting.
- Certent and NetSuite experience preferred.
In accordance with California’s Pay Transparency law, Vaxart’s base salary range for this position is approximately $150,000 - $200,000 USD annually. The actual salary for this role will vary based on a variety of factors including education, job-related knowledge, and experience. This range does not include equity, benefits, bonuses, or other non-monetary compensation which may be included.
Vaxart offers team members a competitive compensation and benefits package, including a robust health plan, bonus program, stock options, 401(k) with employer matching, tuition assistance, and work-life balance.
Vaxart is an Equal Opportunity Employer and values diversity. We are committed to the principles of equal employment opportunity and affirmative action for all applicants and employees. Equal opportunity and consideration are afforded to all qualified applicants and employees in personnel actions, which include recruiting and hiring, selection for training, promotion, rates of pay or other compensation, transfer, discipline, demotion, and layoff or termination. Vaxart does not unlawfully discriminate on the basis of race, color, religion, sexual orientation, marital status, pregnancy, gender identity, gender expression, family medical history or genetic information, citizenship, national origin or ancestry, sex, age, physical or mental disability, medical condition, veteran status, military status, or any other basis protected by.
NOTICE TO RECRUITERS AND STAFFING AGENCIES: Vaxart, Inc. has an internal recruiting department. Vaxart may supplement that internal capability from time to time with assistance from temporary staffing agencies, placement services, and professional recruiters ('Agency'). Agencies are hereby specifically directed NOT to contact Vaxart employees directly to present candidates. Vaxart’s recruiting team or other authorized Vaxart personnel must present ALL candidates to hiring managers.
To protect the interests of all parties, Vaxart will not accept unsolicited resumes from any source other than directly from a candidate. Any unsolicited resumes sent to Vaxart, including unsolicited resumes sent to a Vaxart mailing address, fax machine or email address, directly to Vaxart employees, or to Vaxart's resume database will be considered Vaxart property. Vaxart will NOT pay a fee for any placement resulting from the receipt of an unsolicited resume. Vaxart will consider any candidate for whom an Agency has submitted an unsolicited resume to have been referred by the Agency free of any charges or fees.
The Agency must obtain advance written approval from Vaxart's recruiting function to submit resumes, and then only in conjunction with a valid fully executed contract for service and in response to a specific job opening. Vaxart will not pay a fee to any Agency that does not have such an agreement in place.
Agency agreements will only be valid if in writing and signed by an officer of Vaxart or their designee. No other Vaxart employee is authorized to bind Vaxart to any agreement regarding the placement of candidates by Agencies. Vaxart hereby specifically rejects, and denies any liability under, any agreement purporting to be accepted based on negative consent, negotiation with a candidate, performance, or any means other than the signature of a Vaxart officer.
What We Do
For two hundred years vaccines have been administered by intramuscular injection. Vaxart’s oral vaccine pills may change everything.
Our vaccine pills act differently, by attacking invading pathogens in the places where they first enter the body: the mucosal areas, including the mouth, the nose and the gut. They are designed to trigger strong IgA and T-cell responses to repel and overwhelm the invading viral invaders.
Vaxart has begun Phase II trials of its oral vaccine for Covid and for Norovirus– the only company in the world to reach this stage with a COVID-19 vaccine pill.